Clinical Trial Update: A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the pharmacokinetics and safety of OvaRex MAb-B43.13 in ovarian epithelial carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Epithelial Carcinoma

Drugs mentioned

• OvaRex MAb-B43.13 (MAb-B43.13)

Snippet

Sponsor: Unither Pharmaceuticals | Conditions: Ovarian Neoplasms | Phase 1, Phase 2 | Status: TERMINATED